NOTE: Many features on this website require Javascript and cookies. You can enable both via your browser's preference settings.
NEJM - 04/07/2007 21:55:15
Meta-analyses suggest that the thiazolidinedione rosiglitazone, used in the treatment of type 2 diabetes, may increase the risk of myocardial infarction and death from cardiovascular causes. This interim analysis of an ongoing noninferiority trial of rosiglitazone is inconclusive but does not exclude cardiotoxicity. Because patients with diabetes are already at high risk for cardiovascular disease, it is important that any potential cardiotoxicity of rosiglitazone be reported.
Sign in or register to comment on this story